PET for in vivo pharmacokinetic and pharmacodynamic measurements

Positron emission tomography (PET) scanning is evolving as a unique tool for drug development in oncology for improving both the efficacy of established treatment and in evaluating novel anticancer agents. As a non-invasive functional imaging modality, PET has an unrivalled sensitivity when monitori...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2002-11, Vol.38 (16), p.2094-2107
Main Authors: Gupta, N, Price, P.M, Aboagye, E.O
Format: Article
Language:English
Subjects:
Animals
Antibodies - therapeutic use
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Apoptosis
Cell Division
Cell Hypoxia
Clinical Trials, Phase I as Topic
Drug development
Drug Resistance, Multiple
Humans
Imaging, Three-Dimensional - methods
Neoplasms - diagnostic imaging
Neoplasms - drug therapy
Neoplasms - metabolism
Novel anticancer drugs
PET
Pharmacodynamics
Pharmacokinetics
Prodrugs
Radiopharmaceuticals
Receptors, Drug - analysis
Tomography, Emission-Computed - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Positron emission tomography (PET) scanning is evolving as a unique tool for drug development in oncology for improving both the efficacy of established treatment and in evaluating novel anticancer agents. As a non-invasive functional imaging modality, PET has an unrivalled sensitivity when monitoring the pharmacokinetics and pharmacodynamics of drugs and biochemicals when radiolabelled with short living positron-emitting radioisotopes. This is of particular relevance in assessing newer molecular-targeted therapy where conventional evaluation criteria (maximum tolerated dose and tumour shrinkage for example) may be inappropriate. PET has already been applied to a wide number of drugs to demonstrate activity in vivo from standard chemotherapy such as 5-fluorouracil (5-FU) [ J Clin Oncol 17 (1999) 1580], to novel molecular agents such as those involved in tumour angiogenesis [ Br J Cancer 83 (2000) P6] and antivascular therapy [ Proc Annu Meet Am Soc Clin Oncol 19 (2000) 179a]. This review will evaluate the achievements of PET in the drug development process, an approach that promises to facilitate the rapid translation of scientific research into current clinical practice.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(02)00413-6